世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global myasthenia gravis treatment market is projected to grow significantly at a compound annual growth rate (CAGR) of 8.2%, increasing from a value of USD 2.69 billion in 2025 to USD 4.67 bil... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global myasthenia gravis treatment market is projected to grow significantly at a compound annual growth rate (CAGR) of 8.2%, increasing from a value of USD 2.69 billion in 2025 to USD 4.67 billion by the end of 2032. This growth is driven by advancements in therapeutic approaches and increasing awareness of the disease.Myasthenia Gravis (MG) is an autoimmune disorder characterized by neuromuscular dysfunction, leading to muscle weakness and fatigue. Current treatment strategies aim to enhance neuromuscular transmission and manage autoimmune responses. Therapeutic options include acetylcholinesterase inhibitors, immunosuppressants, and emerging monoclonal antibody therapies. The rising prevalence of MG, particularly in aging populations, and the growing focus on precision medicine are key factors fueling the market expansion. Collaborative efforts between pharmaceutical companies and research institutions are accelerating the development of innovative and targeted treatments. Key Market Drivers 1.Advancements in Immunotherapies: oNovel treatments, including monoclonal antibodies such as eculizumab and rituximab, are transforming MG management. These therapies target specific immune system components, offering precision treatment with improved outcomes. oImmunotherapies continue to evolve, providing advanced tools for addressing the complex immunological aspects of MG. 2.Rising Disease Awareness and Detection: oImproved diagnostic capabilities and awareness campaigns are leading to earlier identification of MG cases. oIncreased recognition of MG by healthcare professionals and the general population supports proactive management and expands treatment demand. Business Opportunities 1.Personalized Therapies: oTailoring treatments to individual patient profiles using precision medicine presents significant potential for improved efficacy and reduced adverse effects. Advances in genetic understanding and immune system dynamics drive the development of personalized therapies. 2.Diversified Therapeutic Modalities: oCompanies exploring novel treatment options such as gene therapies and innovative immunomodulatory agents can unlock untapped market potential. These therapies address unmet medical needs while generating new revenue streams. Regional Analysis 1.Europe: oEurope is emerging as a dominant region due to its strategic healthcare infrastructure and supportive regulatory environment. oAdvanced diagnostic capabilities and specialized neurological treatment centers contribute to rapid adoption of innovative therapies. oThe proactive approach of the European Medicines Agency fosters investor confidence and accelerates research and development initiatives. 2.South Asia & Pacific: oThe region is the fastest-growing market, driven by a rising MG burden, population growth, and improved healthcare awareness. oAwareness campaigns and initiatives encourage early diagnosis and treatment adoption, fueling market growth. Market Challenges 1.Regulatory Complexities: oStringent regulatory requirements for drug approvals can delay market entry for innovative therapies. Companies must navigate these challenges effectively to maintain market competitiveness. 2.Therapeutic Complexity: oMG’s heterogeneous nature necessitates personalized approaches, creating challenges in standardizing treatment protocols. Competitive Analysis Prominent companies leading the myasthenia gravis treatment market include: •Alexion Pharmaceutical Inc. •Grifols SA •Avadel Pharmaceuticals plc. •Novartis AG •Pfizer Inc. •AbbVie Inc. •F. Hoffmann-La Roche Ltd. •GlaxoSmithKline plc •Bausch Health Companies Inc. •Shire plc. Myasthenia Gravis Treatment Market Segmentation 1.By Drug Class: oCholinesterase Inhibitors oCorticosteroids oImmunosuppressants oIntravenous Immunoglobulin (IVIg) oMonoclonal Antibodies 2.By Distribution Channel: oHospital Pharmacies oRetail Pharmacies oOnline Pharmacies 3.By Region: oNorth America oEurope oAsia Pacific oLatin America oMiddle East & Africa Table of Contents1. Executive Summary1.1. Global Myasthenia Gravis Treatment Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Myasthenia Gravis Treatment Market Outlook, 2019 - 2032 3.1. Global Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032 3.1.1. Key Highlights 3.1.1.1. Corticosteroids 3.1.1.2. IVIg 3.1.1.3. Monoclonal Antibodies 3.1.1.4. Immunosuppressants 3.1.1.5. Cholinesterase Inhibitors 3.2. Global Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032 3.2.1. Key Highlights 3.2.1.1. Hospital Pharmacies 3.2.1.2. Retail Pharmacies 3.2.1.3. Online Pharmacies 3.3. Global Myasthenia Gravis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032 4.1. North America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032 4.1.1. Key Highlights 4.1.1.1. Corticosteroids 4.1.1.2. IVIg 4.1.1.3. Monoclonal Antibodies 4.1.1.4. Immunosuppressants 4.1.1.5. Cholinesterase Inhibitors 4.2. North America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032 4.2.1. Key Highlights 4.2.1.1. Hospital Pharmacies 4.2.1.2. Retail Pharmacies 4.2.1.3. Online Pharmacies 4.3. North America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032 4.3.1. Key Highlights 4.3.1.1. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 4.3.1.2. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 4.3.1.3. Canada Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 4.3.1.4. Canada Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Myasthenia Gravis Treatment Market Outlook, 2019 - 2032 5.1. Europe Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032 5.1.1. Key Highlights 5.1.1.1. Corticosteroids 5.1.1.2. IVIg 5.1.1.3. Monoclonal Antibodies 5.1.1.4. Immunosuppressants 5.1.1.5. Cholinesterase Inhibitors 5.2. Europe Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.2.1. Key Highlights 5.2.1.1. Hospital Pharmacies 5.2.1.2. Retail Pharmacies 5.2.1.3. Online Pharmacies 5.3. Europe Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032 5.3.1. Key Highlights 5.3.1.1. Germany Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.2. Germany Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.1.3. U.K. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.4. U.K. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.1.5. France Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.6. France Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.1.7. Italy Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.8. Italy Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.1.9. Turkey Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.10. Turkey Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.1.11. Russia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.12. Russia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.1.13. Rest of Europe Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 5.3.1.14. Rest of Europe Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Myasthenia Gravis Treatment Market Outlook, 2019 - 2032 6.1. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032 6.1.1. Key Highlights 6.1.1.1. Corticosteroids 6.1.1.2. IVIg 6.1.1.3. Monoclonal Antibodies 6.1.1.4. Immunosuppressants 6.1.1.5. Cholinesterase Inhibitors 6.2. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.2.1. Key Highlights 6.2.1.1. Hospital Pharmacies 6.2.1.2. Retail Pharmacies 6.2.1.3. Online Pharmacies 6.3. Asia Pacific Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032 6.3.1. Key Highlights 6.3.1.1. China Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 6.3.1.2. China Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.3.1.3. Japan Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 6.3.1.4. Japan Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.3.1.5. South Korea Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 6.3.1.6. South Korea Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.3.1.7. India Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 6.3.1.8. India Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.3.1.9. Southeast Asia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 6.3.1.10. Southeast Asia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.3.1.11. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 6.3.1.12. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032 7.1. Latin America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032 7.1.1. Key Highlights 7.1.1.1. Corticosteroids 7.1.1.2. IVIg 7.1.1.3. Monoclonal Antibodies 7.1.1.4. Immunosuppressants 7.1.1.5. Cholinesterase Inhibitors 7.2. Latin America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032 7.2.1. Key Highlights 7.2.1.1. Hospital Pharmacies 7.2.1.2. Retail Pharmacies 7.2.1.3. Online Pharmacies 7.3. Latin America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032 7.3.1. Key Highlights 7.3.1.1. Brazil Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 7.3.1.2. Brazil Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 7.3.1.3. Mexico Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 7.3.1.4. Mexico Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 7.3.1.5. Argentina Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 7.3.1.6. Argentina Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 7.3.1.7. Rest of Latin America Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 7.3.1.8. Rest of Latin America Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, 2019 - 2032 8.1. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032 8.1.1. Key Highlights 8.1.1.1. Corticosteroids 8.1.1.2. IVIg 8.1.1.3. Monoclonal Antibodies 8.1.1.4. Immunosuppressants 8.1.1.5. Cholinesterase Inhibitors 8.2. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032 8.2.1. Key Highlights 8.2.1.1. Hospital Pharmacies 8.2.1.2. Retail Pharmacies 8.2.1.3. Online Pharmacies 8.3. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032 8.3.1. Key Highlights 8.3.1.1. GCC Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 8.3.1.2. GCC Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 8.3.1.3. South Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 8.3.1.4. South Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 8.3.1.5. Egypt Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 8.3.1.6. Egypt Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 8.3.1.7. Nigeria Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 8.3.1.8. Nigeria Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 8.3.1.9. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032 8.3.1.10. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Market Share Analysis, 2025 9.2. Competitive Dashboard 9.3. Company Profiles 9.3.1. Grifols SA 9.3.1.1. Company Overview 9.3.1.2. Product Portfolio 9.3.1.3. Financial Overview 9.3.1.4. Business Strategies and Development 9.3.2. Pfizer, Inc. 9.3.2.1. Company Overview 9.3.2.2. Product Portfolio 9.3.2.3. Financial Overview 9.3.2.4. Business Strategies and Development 9.3.3. AbbVie Inc. 9.3.3.1. Company Overview 9.3.3.2. Product Portfolio 9.3.3.3. Financial Overview 9.3.3.4. Business Strategies and Development 9.3.4. GSK 9.3.4.1. Company Overview 9.3.4.2. Product Portfolio 9.3.4.3. Financial Overview 9.3.4.4. Business Strategies and Development 9.3.5. Novartis AG 9.3.5.1. Company Overview 9.3.5.2. Product Portfolio 9.3.5.3. Financial Overview 9.3.5.4. Business Strategies and Development 9.3.6. Alexion Pharmaceutical Inc. 9.3.6.1. Company Overview 9.3.6.2. Product Portfolio 9.3.6.3. Financial Overview 9.3.6.4. Business Strategies and Development 9.3.7. F. Hoffman-La Roche Ltd. 9.3.7.1. Company Overview 9.3.7.2. Product Portfolio 9.3.7.3. Financial Overview 9.3.7.4. Business Strategies and Development 9.3.8. Bausch Health Companies Inc. 9.3.8.1. Company Overview 9.3.8.2. Product Portfolio 9.3.8.3. Financial Overview 9.3.8.4. Business Strategies and Development 9.3.9. Shire plc. 9.3.9.1. Company Overview 9.3.9.2. Product Portfolio 9.3.9.3. Financial Overview 9.3.9.4. Business Strategies and Development 9.3.10. Avadel Pharmaceuticals plc. 9.3.10.1. Company Overview 9.3.10.2. Product Portfolio 9.3.10.3. Financial Overview 9.3.10.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社のヘルスケアIT分野での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
